$0.27
▼ -5.0% Today
as of Jul 23, 11:10 ET
Last 30 days
Recent Press Releases & News
Valion Bio's Entolimod Accepted for Regulatory Review in Ukraine
Valion Bio Advances Entolimod Program with Government Engagement, Manufacturing Scale-Up, Oncology Supportive Care Plans
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
Overview
52-week range
$0.60
$5.60
0% of range
Avg surprise (last 0)
—
Avg reaction (last 2)
-1.9%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-2.23 | — | — | +11.5% | -3.8% | earnings |
| Thu Aug 14, 2025 | Jun/2025 | $-2.19 | — | — | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-2.52 | — | — | — | 0.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.23 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-5.37 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-17.15 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.48 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-7.16 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | — | -$2.19 |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $86,000 | $70,000 | — | $126,000 | $140,000 |
| Cost of revenue | — | — | — | $32,000 | $20,000 | — | $82,000 | $110,000 |
| Gross profit | — | — | $-145,000 | $54,000 | $50,000 | — | $44,000 | $30,000 |
| Operating income | $-6M | — | $-2M | $-2M | $-1M | — | $-1M | $-1M |
| Net income | $-6M | — | $-3M | $-2M | $-2M | — | $-1M | $-1M |
| EPS (diluted) | — | — | — | $-2.19 | $-2.52 | — | $-0.23 | $-5.37 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7M | $13M | $3M | $1M | $669,000 | $2M | $2M | $4M |
| Inventory | $750,000 | $0 | $4,000 | $283,000 | $306,000 | $319,000 | $731,000 | $766,000 |
| Total current assets | $9M | $13M | $4M | $2M | $1M | $3M | $3M | $5M |
| Total assets | $38M | $32M | $6M | $5M | $4M | $3M | $3M | $5M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $20M | $7M | $638,000 | $821,000 | $741,000 | $272,000 | $560,000 | $591,000 |
| Total equity | $11M | $17M | $6M | $4M | $3M | $3M | $3M | $4M |
Implied volatility — last 90 days
No IV snapshots yet for VBIO.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.